ClinicalTrials.gg
Not yet recruitingNCT07939763Updated Nov 16, 2026

Effects of Video-Based Education on Symptom Management Self-Efficacy and Quality of Life in Women Receiving Chemotherapy for Breast Cancer

An interventional study of Video-Based Symptom Management Education in Breast Cancer, sponsored by Antalya Bilim University. Not yet recruiting at 1 site in Turkey (Türkiye). Open to female participants, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Antalya Bilim University · Not applicable, Interventional, and Supportive care

Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 397 studies in Breast Neoplasms with a site in Turkey — 82 open to participants now, 128 under way, 46 of them phase 3. Breast Neoplasms · Turkey.

Planned enrollment
169th of 319
90 · median 102
Started
2026
with 38 others
No phase
182 of 397
48 open now
Primary completion
2027-02
later than 83 of 127 live
Registered
397th of 397
by date

Among the 397 studies in Breast Neoplasms with a site in Turkey, this one is the 169th largest by planned enrollment of the 319 interventional ones that give a count, is one of 39 that started in 2026, is one of 182 with no phase, reaches primary completion later than 83 of the 127 other live ones, and was the 397th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

82 of the 397 studies in Breast Neoplasms with a site in Turkey are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 397 studies in Breast Neoplasms with a site in Turkey, or all of them as a file.
02

Study summary

This study is designed as a randomized controlled trial to evaluate the effect of a video-based educational intervention on symptom management self-efficacy and quality of life in women diagnosed with breast cancer who are receiving chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of female patients diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be divided into two groups: an intervention group and a control group.

Read the detailed description

This study is designed as a randomized controlled trial to evaluate the impact of a video-based educational intervention on self-efficacy for symptom management and quality of life in women diagnosed with breast cancer who are undergoing chemotherapy. The study will be conducted at the Day Chemotherapy Unit of Akdeniz University Hospital. The study sample will consist of women diagnosed with breast cancer who meet the inclusion criteria and consent to participate. Participants will be assigned to either an intervention group or a control group. The sample size was calculated using the G*Power 3.1.9 software, determining that a minimum of 72 participants-36 in each group-are required. Accounting for potential attrition, the study is planned to include a total of 90 participants, with 45 in the intervention group and 45 in the control group. In addition to routine care, patients in the intervention group will receive support for symptom management through a video-based educational intervention over a period of 8 weeks. Patients in the control group will receive the standard routine care provided at the study site. Data will be collected at three time points: baseline (T0), an interim follow-up (T1), and a final post-test (T2). The primary outcomes of the study are the level of self-efficacy regarding chemotherapy symptom management and quality of life. Secondary outcomes include the usability of the video-based educational intervention and instances of unplanned healthcare utilization (such as emergency department visits or unplanned hospital readmissions). Data collection will involve the use of a "Patient Information Form," the "Chemotherapy Symptom Management Self-Efficacy Scale for Breast Cancer," the "Functional Assessment of Cancer Therapy - Breast (FACT-B)," the "System Usability Scale," and a "Healthcare Utilization and Readmission Form" developed by the researcher. Data obtained from the study will be analyzed using the SPSS software package. It is anticipated that the video-based educational intervention will increase self-efficacy in symptom management among women diagnosed with breast cancer, improve their quality of life, and reduce the utilization of healthcare services, such as emergency department visits and hospital readmissions.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • chemotherapy
  • breast cancer
  • self-efficacy
  • symptom management
  • video-based education
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Being 18 years of age or older,
  • Being able to read and write in Turkish,
  • Having no barriers to written or verbal communication,
  • Being newly diagnosed with breast cancer and being aware of the diagnosis,
  • Having received at least two cycles of chemotherapy,
  • Having access to an internet-enabled digital device (e.g., smartphone), either personally owned or shared with family members, and being able to use it actively,
  • Having an (ECOG) Performance Status of 0-2.

Exclusion criteria

Exclusion Criteria:

  • Patients who do not agree to participate in the study,
  • Patients participating in another study related to symptom management,
  • Patients with a history of diagnosed psychiatric disorders,
  • Patients with an (ECOG) Performance Status of 3 or higher.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    INTERVENTION GROUP

    In addition to routine care, patients in the intervention group will receive symptom management support over an 8-week period through a video-based educational intervention.

    Behavioral: Video-Based Symptom Management Education

  • No intervention
    CONTROL GROUP

    Patients in the control group will receive the routine care provided at the center where the study is being conducted.

Interventions

  • BehavioralVideo-Based Symptom Management Education

    Participants in the intervention group will receive an 8-week video-based educational intervention in addition to standard care. The web-based platform will provide evidence-based educational videos on chemotherapy-related symptoms and symptom management. Participants will be directed to symptom-specific videos through a rule-based algorithm based on their self-reported symptoms. They will be asked to access the platform at least three times per week and will receive reminder messages twice weekly. Platform usage will be monitored, and post-intervention assessments will be conducted after the 8-week intervention.

06

What researchers measure

Primary outcomes

  1. Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC)

    Symptom management self-efficacy will be assessed using the Symptom Management Self-Efficacy Scale for Breast Cancer Related to Chemotherapy (SMSES-BC). Changes in self-efficacy scores will be evaluated across three assessment points.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2).

  2. Functional Assessment of Cancer Therapy-Breast (FACT-B)

    Quality of life will be assessed using the Functional Assessment of Cancer Therapy-Breast (FACT-B). Changes in quality-of-life scores will be evaluated across three assessment points.

    Time frame: Baseline (T0), Week 4 (T1), and Week 8 (T2).

Secondary outcomes

  1. System Usability Scale (SUS)

    System usability will be assessed in the intervention group using the System Usability Scale (SUS) to evaluate participants' perceptions of the video-based educational platform.

    Time frame: At the end of the intervention (T2).

  2. Hospital Readmissions

    Hospital readmissions will be assessed using a researcher-developed healthcare utilization form, including the occurrence, frequency, and duration of hospital readmissions during the 8-week study period.

    Time frame: Week 8 (T2), covering the previous 8 weeks.

  3. Emergency Department Visits

    The number and reasons for emergency department visits during the 8-week study period will be assessed using a researcher-developed healthcare utilization form.

    Time frame: Week 8 (T2), covering the previous 8 weeks.

  4. Unplanned Healthcare Visits

    The frequency and reasons for unplanned outpatient clinic visits and other healthcare facility visits will be assessed using a researcher-developed healthcare utilization form.

    Time frame: Week 8 (T2), covering the previous 8 weeks.

  5. Treatment-Related Economic Burden

    Treatment-related economic burden will be assessed using a researcher-developed form to evaluate the financial burden associated with healthcare utilization during the study period.

    Time frame: Week 8 (T2), covering the previous 8 weeks.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2027, 2 months later.

Of 2,663 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 2 months is below that.

Counting every sponsor, half of 2,773 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 16, 2026
StartEst.
Dec 1, 2026
Primary completionEst.
Feb 1, 2027
CompletionEst.
May 1, 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07939763
Lead sponsor
Antalya Bilim University
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Dec 1, 2026 (estimated)
Primary completion
Feb 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Ümmühan Duman
Contact
ummuhan.duman@antalya.edu.tr
02422450000/3314
Ümmühan Duman
principal investigator · Antalya Bilim University- ummuhan.duman@antalya.edu.tr

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion